Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2019

01-11-2019 | Warfarin

Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy

Authors: Jessica L. Cohen, Elena Thompson, Liron Sinvani, Andrzej Kozikowski, Guang Qiu, Renee Pekmezaris, Alex C. Spyropoulos, Jason J. Wang

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2019

Login to get access

Abstract

This study evaluates three warfarin dosing algorithms (Kimmel, Dawson, High Dose ≥ 2.5 mg) for hospitalized older adults. A random selection of 250 patients with overshoots (INR ≥ 5 after 48 h of hospitalization) and 250 patients without overshoots were accessed from a database of 12,107 inpatients ≥ 65 years treated with chronic warfarin during hospitalization between January 1, 2014 and June 30, 2016. Algorithms were retrospectively applied to patients 2 days prior to overshoots in the overshoot group, and 2 days prior to the maximum INR reached after 48 h of hospitalization in the non-overshoot group. Patients were categorized as overdosed or not overdosed and compared using descriptive statistics. Logistic regression modeling determined predictors for overshoots. There was no significant difference between overdose and non-overdose groups for progressing to overshoots by the Kimmel (51.0% vs. 48.7%, p = 0.67) or Dawson (48.5 vs. 57.9%, p = 0.19) algorithms. The Low Dose Group (≤ 2.5 mg) was significantly more likely to experience an overshoot than the High Dose Group (56.6% vs. 45.5%, p = 0.04). The Low Dose Group was more likely to be older (81.4% vs. 71.1%, p = 0.02), female (63.5% vs. 49.8%, p = 0.02), weigh less (71.3 ± 21.9 vs. 79 ± 23.1, p = 0.002), and be prescribed amiodarone (16.6% vs. 8.1%, p = 0.01). While none of the algorithms predicted overshoots in logistic regression modeling, weight over 70 kg and black race remained protective. The High Dose Algorithm revealed that providers appropriately gave lower doses to patients at highest risk for warfarin sensitivity. Future studies are needed to investigate tools for inpatient warfarin dosing in older adults.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dregan A, Ravindrarajah R, Charlton J, Ashworth M, Molokhia M (2018) Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol 28:440–446CrossRefPubMed Dregan A, Ravindrarajah R, Charlton J, Ashworth M, Molokhia M (2018) Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol 28:440–446CrossRefPubMed
2.
go back to reference Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 112(8):1142–1147CrossRefPubMed Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 112(8):1142–1147CrossRefPubMed
4.
go back to reference Classen DC, Jaser L, Budnitz DS (2010) Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 36(1):12–21CrossRefPubMed Classen DC, Jaser L, Budnitz DS (2010) Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 36(1):12–21CrossRefPubMed
5.
go back to reference Harris Y, Hu DJ, Lee C, Mistry M, York A, Johnson TK (2015) Advancing medication safety: establishing a national action plan for adverse drug event prevention. Jt Comm J Qual Patient Saf. 41(8):351–360CrossRefPubMed Harris Y, Hu DJ, Lee C, Mistry M, York A, Johnson TK (2015) Advancing medication safety: establishing a national action plan for adverse drug event prevention. Jt Comm J Qual Patient Saf. 41(8):351–360CrossRefPubMed
6.
go back to reference Kim Y-K, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N et al (2010) Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost. 8(1):101–106CrossRefPubMed Kim Y-K, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N et al (2010) Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost. 8(1):101–106CrossRefPubMed
7.
go back to reference Garcia DA, Schwartz MJ (2011) Warfarin therapy: tips and tools for better control: monitoring patients on warfarin therapy is challenging. The tools highlighted here–from online forums and Web-based dosing calculators to patient education materials and self-monitors–can help. J Fam Pract 60(2):70–76PubMed Garcia DA, Schwartz MJ (2011) Warfarin therapy: tips and tools for better control: monitoring patients on warfarin therapy is challenging. The tools highlighted here–from online forums and Web-based dosing calculators to patient education materials and self-monitors–can help. J Fam Pract 60(2):70–76PubMed
8.
go back to reference Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S et al (2012) Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the RE-LY trial. Circulation. 126:2309–2316CrossRefPubMed Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S et al (2012) Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the RE-LY trial. Circulation. 126:2309–2316CrossRefPubMed
9.
go back to reference Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentral Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentral
10.
go back to reference Dawson NL, Porter IE, Klipa D, Bamlet WR, Hedges MA, Maniaci MJ et al (2012) Inpatient warfarin management: pharmacist management using a detailed dosing protocol. J Thromb Thrombolysis 33(2):178–184CrossRefPubMed Dawson NL, Porter IE, Klipa D, Bamlet WR, Hedges MA, Maniaci MJ et al (2012) Inpatient warfarin management: pharmacist management using a detailed dosing protocol. J Thromb Thrombolysis 33(2):178–184CrossRefPubMed
12.
go back to reference Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126(2):133–136CrossRefPubMed Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126(2):133–136CrossRefPubMed
13.
go back to reference Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA (2010) Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm 67(18):1554–1556CrossRefPubMed Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA (2010) Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm 67(18):1554–1556CrossRefPubMed
15.
go back to reference Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3):326–331CrossRefPubMedPubMedCentral Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3):326–331CrossRefPubMedPubMedCentral
16.
go back to reference Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283–2293CrossRefPubMedPubMedCentral Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283–2293CrossRefPubMedPubMedCentral
Metadata
Title
Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy
Authors
Jessica L. Cohen
Elena Thompson
Liron Sinvani
Andrzej Kozikowski
Guang Qiu
Renee Pekmezaris
Alex C. Spyropoulos
Jason J. Wang
Publication date
01-11-2019
Publisher
Springer US
Keyword
Warfarin
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01902-0

Other articles of this Issue 4/2019

Journal of Thrombosis and Thrombolysis 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.